Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Gets FTC Nod For Custopharm Deal – But With Strings Attached

Acquisition Moves Closer To Completion, But Combining Firms Must Lose A Product

Executive Summary

Hikma has moved closer to completing a deal worth more than $400m to acquire Custopharm, which promises to bolster its US injectables business. However, the FTC’s approval of the transaction comes with conditions.

You may also be interested in...



Hikma Outlines Injectables Growth Amid Slow Start For Generics

Hikma has set out fresh growth forecasts for its injectables business after completing its acquisition of Custopharm. Meanwhile, a slow start to the year for the firm’s generics business amid a “challenging pricing environment” is expected to be followed by higher revenues towards the end of the year.

Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

Hikma’s Injectables Business Expands As It Completes Custopharm Acquisition

Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel